Roche’s Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Metastatic Triple-Negative Breast Cancer


  • The P-III IMpassion131 study involves assessing of Tecentriq + paclitaxel vs PBO + paclitaxel, in 651 people in a ratio (2:1) with previously untreated, inoperable, LA/ m-TNBC
  • The study did not meet its 1EPs of PFS for 1L treatment of people with m-TNBC) in the PD-L1+ population.  The data for 2EPs of OS showed a negative trend, however, the study was not powered for the 2EPs of OS and data were immature at the time of analysis while OS follow-up is planned to continue until the final analysis
  • In the previous IMpassion130 study, Tecentriq + Abraxane demonstrated PFS benefit and, while not formally tested, showed improvements in OS for people with metastatic TNBC whose tumors express PD-L1

Click here ­to­ read full press release/ article | Ref: Roche | Image: Forbes

Related News: Roche’s Tecentriq (atezolizumab) + Abraxane Receive European Commission’s Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer